Checkpoint Therapeutics (NasdaqCM:CKPT) - Share price, News & Analysis

Q: What is the Fair Price of CKPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CKPT ($1.12) is trading below our estimate of [[fair value]] ($169.87)

CKPT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

CKPT Stock Overview

Rewards

Trading at 99.3% below our estimate of its fair value

Earnings are forecast to grow 67.89% per year

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($252K)

Volatile share price over the past 3 months

Significant insider selling over the past 3 months

+ 1 more risk

Checkpoint Therapeutics Competitors

Entasis Therapeutics Holdings

NasdaqGM:ETTX

US$105.3m

Capricor Therapeutics

NasdaqCM:CAPR

US$109.7m

Palatin Technologies

NYSEAM:PTN

US$71.2m

Outlook Therapeutics

NasdaqCM:OTLK

US$246.3m

Price History & Performance

Summary of all time highs, changes and price drops for Checkpoint Therapeutics
Historical stock prices
Current Share Price	US$1.12
52 Week High	US$4.64
52 Week Low	US$0.96
Beta	1.7
1 Month Change	-20.57%
3 Month Change	-34.88%
1 Year Change	-62.79%
3 Year Change	-63.04%
5 Year Change	-88.74%
Change since IPO	-77.60%

Recent News & Updates

May 18

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

	CKPT	US Biotechs	US Market
7D	7.7%	10.3%	6.6%
1Y	-62.8%	-24.3%	-18.4%

Return vs Industry: CKPT underperformed the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: CKPT underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is CKPT's price volatile compared to industry and market?
CKPT volatility
CKPT Average Weekly Movement	12.9%
Biotechs Industry Average Movement	13.2%
Market Average Movement	8.1%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.2%

Stable Share Price: CKPT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: CKPT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2014	14	James Oliviero	https://www.checkpointtx.com

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company’s lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.

Checkpoint Therapeutics Fundamentals Summary

How do Checkpoint Therapeutics's earnings and revenue compare to its market cap?
CKPT fundamental statistics
Market Cap	US$109.64m
Earnings (TTM)	-US$67.01m
Revenue (TTM)	US$252.00k

435.8x

P/S Ratio

-1.6x

P/E Ratio

Is CKPT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
CKPT income statement (TTM)
Revenue	US$252.00k
Cost of Revenue	US$48.45m
Gross Profit	-US$48.20m
Other Expenses	US$18.81m
Earnings	-US$67.01m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.68
Gross Margin	-19,127.38%
Net Profit Margin	-26,592.46%
Debt/Equity Ratio	0.0%

How did CKPT perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is CKPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CKPT?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for CKPT. This is calculated by dividing CKPT's market cap by their current preferred multiple.
What is CKPT's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$109.64m

CKPT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	270.5x
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does CKPT's PB Ratio compare to its peers?

CKPT PB Ratio vs Peers

The above table shows the PB ratio for CKPT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	5x
ETTX Entasis Therapeutics Holdings	6.3x	52.3%	US$105.3m
CAPR Capricor Therapeutics	4.5x	-16.6%	US$109.7m
PTN Palatin Technologies	2.5x	15.0%	US$71.2m
OTLK Outlook Therapeutics	6.8x	74.0%	US$246.3m
CKPT Checkpoint Therapeutics	5.4x	67.9%	US$109.6m

Price-To-Book vs Peers: CKPT is expensive based on its Price-To-Book Ratio (5.4x) compared to the peer average (5x).

Price to Earnings Ratio vs Industry

How does CKPT's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: CKPT is expensive based on its Price-To-Book Ratio (5.4x) compared to the US Biotechs industry average (1.6x)

Price to Book Ratio vs Fair Ratio

What is CKPT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CKPT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	5.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CKPT's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of CKPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CKPT ($1.12) is trading below our estimate of fair value ($169.87)

Significantly Below Fair Value: CKPT is trading below fair value by more than 20%.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CKPT's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Checkpoint Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

67.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CKPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: CKPT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CKPT is expected to become profitable in the next 3 years.

Revenue vs Market: CKPT's revenue (71.8% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: CKPT's revenue (71.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CKPT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Checkpoint Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-12.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CKPT is currently unprofitable.

Growing Profit Margin: CKPT is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: CKPT is unprofitable, and losses have increased over the past 5 years at a rate of 12.7% per year.

Accelerating Growth: Unable to compare CKPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CKPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: CKPT has a negative Return on Equity (-331.48%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Checkpoint Therapeutics's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CKPT's short term assets ($42.9M) exceed its short term liabilities ($22.7M).

Long Term Liabilities: CKPT has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: CKPT is debt free.

Reducing Debt: CKPT had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CKPT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CKPT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.3% each year

Discover healthy companies

Dividend

What is Checkpoint Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CKPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CKPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CKPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CKPT's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CKPT has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.9yrs

Average board tenure

CEO

James Oliviero (45 yo)

6.67yrs

Tenure

US$2,292,370

Compensation

Mr. James F. Oliviero, III, CFA has been the Chief Executive Officer and President of Checkpoint Therapeutics, Inc. since October 16, 2015 and also has been its Director since October 15, 2018. Mr. Olivier...

CEO Compensation Analysis

Compensation vs Market: James's total compensation ($USD2.29M) is above average for companies of similar size in the US market ($USD749.40K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.

Board Members

Experienced Board: CKPT's board of directors are considered experienced (4.9 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: CKPT insiders have only sold shares in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.6%.

Data	Last Updated (UTC time)
Company Analysis	2022/06/26 00:00
End of Day Share Price	2022/06/24 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31